crine IGF-I, which in turn inhibits neighbouring somatotroph transcription (8) , In addition, intrapituitary IGF-I also appears to regulate somatotroph function by an autocrine, or possibly an intracrine mechanism, as IGF-I is coexpressed with GH in somatotroph cells. As pituitary IGF-I gene expression is regulated in a GH-dependent manner, a closed autocrine loop may also be operative in the mutual feedback regulation of these two anabolic polypeptide hormones (9) .~S irttcttrre^function studies or the pituitary IGF-I receptor have revealed that the major determinant of somatotroph sensitivity to circulating or intrapituitary IGF-I is the relative abundance of somatotroph IGF receptors (8) . Furthermore, mutation of key signaling motifs (9SOTyr) of the somatotroph IGF-I receptor abrogates IGF-I-mediated GH suppression (10) . Thus, intrapituitary negative feedback of IGF-I on GH transcription is mediated by the intact IGF-I receptor (11, 12) . Thus, pituitary IGF-I receptor integrity may determine the well-known physiologic GH responses to malnutrition, pregnancy, and refeeding (10) .
In this issue of the journal, Stefaneanu and colleagues (13) have employed a transgenic mouse model with disrupted IGF-I gene expression to further elucidate the role of IGF-I in deterrnining somatotroph function. In homozygous IGF-I female knockout mice, somatotroph GH mRNA signals were enhanced, and the pituitary gland exhibited ultrastructural features of somatotroph stimulation, despite unchanged absolute numbers of somatotrophs. Replacement of IGF-I to the homozygote animals decreased pituitary GH mRNA levels as assessed by in situ hybridization signals. This latter finding strongly supports the role of endocrine-derived IGP-I in suppressing pituildj.}' GH synthesis. Although the dwarf IGF-I knockout animals were not sufficiently large enough to provide multiple samplings for meaningful assays of GH secretion, previous workers had shown that circulating GH levels were indeed elevated in another model of IGF-I deficiency. Thus, using novel techniques, this work shows that deprivation of IGF-I leads to compensatory somatotroph hyperfunction. It will be interesting to determine the relative influence of potentially attenuated hypothalamic SPJF in these animals to further elucidate the respective'roles of the hypothalamus and pituitary in mediating these responses.
An unexpected finding in this work was the pronounced effect of IGF-I disruption on PRL synthesis and secretion. It had been recognized from earlier in vitro models that insulin and IGF-I both induce PRL gene transcription and secretion (14) . Surprisingly, although PRL levels were elevated in homozygous IGF-I knockouts, pituitary PRL mRNA levels were significantly lowered. Curiously, IGF-I treatment only increased pituitary PRL mRNA in WT but not in knockout animals. Clearly, further work is required to elucidate the impact of IGF-I on in vivo PRL synthesis and secretion.
Thus, Stefaneanu and colleagues, by using transgenic tech-EDITORIAL Endo • 1999 Vol 140 . No 9 nology, now confirm the role of endocrine-derived IGF-I in regulating both somatotroph function as well as size. Based upon these new findings, and previous data, it is clear that negative feedback regulation of pituitary function involves integration of complex endocrine, paracrine, and autocrine IGF-I-mediated signals, all of which converge on the somatotroph and account for the ultimate secretory pattern of GH (15 
